Search results for "Vascular"

showing 10 items of 10708 documents

COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up

2020

Coronavirus disease-2019 (COVID-19), a viral respiratory illness caused by the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2), may predispose patients to thrombotic disease, both in the venous and arterial circulations, because of excessive inflammation, platelet activation, endothelial dysfunction, and stasis. In addition, many patients receiving antithrombotic therapy for thrombotic disease may develop COVID-19, which can have implications for choice, dosing, and laboratory monitoring of antithrombotic therapy. Moreover, during a time with much focus on COVID-19, it is critical to consider how to optimize the available technology to care for patients without COVID-19 who hav…

medicine.medical_specialtymedicine.drug_classantithrombotic therapyCoronavirus disease 2019; SARS-CoV-2; anticoagulant; antiplatelet; antithrombotic therapy; thrombosisDisease030204 cardiovascular system & hematologyantiplateletPathogenesis03 medical and health sciences0302 clinical medicineAntithromboticEpidemiologyMedicine030212 general & internal medicinePlatelet activationEndothelial dysfunctionIntensive care medicinethrombosisCoronavirus disease 2019SARS-CoV-2business.industryanticoagulantAnticoagulantmedicine.diseaseThrombosisCardiology and Cardiovascular MedicinebusinessJournal of the American College of Cardiology
researchProduct

New approaches on diagnosis and treatment of venous thromboembolism

2014

Summary Pulmonary embolism (PE) and deep vein thrombosis (DVT) are two clinical presentations of venous thromboembolism (VTE) and share the same predisposing factors. In patients admitted to a hospital the rationale use of thromboprophylaxis is based on the high prevalence of VTE amongst hospitalised patients, the adverse consequences of unprevented VTE, and the efficacy of thromboprophylaxis. There is no doubt about the benefit/risk ratio of perioperative venous thromboembolism prophylaxis, but for a safety performance of regional anaesthesia, particularly neuraxial blocks, an appropriate management based on safety intervals suited to the characteristics of the drug is needed. The first st…

medicine.medical_specialtymedicine.drug_classbusiness.industryDeep veinLow molecular weight heparinPerioperativeCritical Care and Intensive Care Medicinemedicine.diseaseThrombosisPulmonary embolismAnesthesiology and Pain Medicinemedicine.anatomical_structureRelative riskmedicinecardiovascular diseasesIntensive care medicineGeneva scorebusinessVenous thromboembolismTrends in Anaesthesia and Critical Care
researchProduct

Ibandronic acid subsequent to raloxifene: Effect on bone metabolism and on cardiovascular risk factors

2015

s / Maturitas 81 (2015) 144–190 161 Materials andmethods: This randomized double-blind clinical trialwas carried out inAhvaz (Iran) fromAugust toDecember 2010. Forty postmenopausal women with symptoms of vaginal atrophy were randomly allocated to two groups to take vaginal suppositories of either 5mg hyaluronic acid sodium salt (n=20) or 1mg vitamin E (n=20) for 8 weeks. The symptoms of vaginal atrophy were evaluated by a self-assessed 4-point scale and the composite score was determined as none, mild, moderate, and severe in four periods. Results: The results showed that the symptoms were relieved significantly in both groups (P<0.001). The relief of symptomswas significantly superior in t…

medicine.medical_specialtymedicine.drug_classbusiness.industryVitamin Emedicine.medical_treatmentCardiovascular risk factorsObstetrics and Gynecologymedicine.diseaseGastroenterologyIbandronic acidGeneral Biochemistry Genetics and Molecular BiologyBone remodelingchemistry.chemical_compoundEndocrinologychemistryEstrogenInternal medicineHyaluronic acidmedicineRaloxifeneVaginal atrophybusinessmedicine.drugMaturitas
researchProduct

Antihistamine-resistant Angioedema in Women with Negative Family History: Estrogens and F12 Gene Mutations

2013

Abstract Background In women with sporadic recurrent angioedema with an unknown cause who are unresponsive to antihistamines and have normal C1 inhibitor activity and a negative family history of angioedema, it is unclear whether they have idiopathic angioedema or hereditary angioedema with normal C1 inhibitor, and what impact exogenous estrogens have on their angioedema. Methods A cohort of 147 women was analyzed for F12 exon 9 mutations and for the influence of oral contraceptives, hormonal replacement therapy, and pregnancy on their angioedema. Results A total of 142 women had idiopathic angioedema unresponsive to antihistamines. Five women had an F12 mutation and thereby hereditary angi…

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentGene mutationC1-inhibitorimmune system diseasesInternal medicinemedicineHereditary Angioedema Type IIIcardiovascular diseasesFamily historyskin and connective tissue diseasesbiologyAngioedemabusiness.industryfood and beveragesGeneral Medicinemedicine.diseaseDermatologyEndocrinologyEstrogenHereditary angioedemabiology.proteinAntihistaminemedicine.symptombusinessThe American Journal of Medicine
researchProduct

Women, thrombosis, and cancer: A gender-specific analysis.

2017

Venous thromboembolism (VTE) is a major common complication in cancer patients. Risk-adapted thromboprophylaxis and antithrombotic therapy for patients diagnosed with VTE can reduce the recurrence of VTE events. Thrombotic risk varies according to cancer type, stage, and comorbidities. The current review analyzes most recent data and provides clinical guidance for the management of women with cancer-associated thrombosis.

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentPregnancy Complications CardiovascularLow molecular weight heparin030204 cardiovascular system & hematologyPregnancy Complications Cardiovascular/drug therapy/epidemiology03 medical and health sciences0302 clinical medicinePregnancyRisk FactorsInternal medicineNeoplasmsAntithromboticMedicineHumanscardiovascular diseasesddc:616Venous Thromboembolism/drug therapy/epidemiologybusiness.industryAromatase InhibitorsAnticoagulantCancerAnticoagulantsThrombosisHematologyVenous Thromboembolismmedicine.diseaseequipment and suppliesThrombosisNeoplasms/complications/epidemiologySurgeryPostmenopauseVenous thrombosisAnticoagulants/therapeutic use030220 oncology & carcinogenesisFemaleHormone therapybusinessComplicationPregnancy Complications NeoplasticPregnancy Complications Neoplastic/epidemiologyThrombosis/drug therapy/epidemiologyAromatase Inhibitors/therapeutic useThrombosis research
researchProduct

Impact of Proportionality of Secondary Mitral Regurgitation on Outcome After Transcatheter Mitral Valve Repair

2020

The purpose of this paper was to evaluate the impact of proportionality of secondary mitral regurgitation (SMR) in a large real-world registry of transcatheter edge-to-edge mitral valve repair (TMVr) BACKGROUND: Differences in the outcomes of recent randomized trials of TMVr for SMR may be explained by the proportionality of SMR severity to left ventricular (LV) volume.The ratio of pre-procedural effective regurgitant orifice area (EROA) to LV end-diastolic volume (LVEDV) was retrospectively assessed in patients undergoing TMVr for severe SMR between 2008 and 2019 from the EuroSMR registry. A recently proposed SMR proportionality scheme was adapted to stratify patients according to EROA/LVE…

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentRenal function030204 cardiovascular system & hematology030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinePredictive Value of TestsInternal medicinemedicineNatriuretic peptideHumansRadiology Nuclear Medicine and imagingRetrospective StudiesBody surface areaMitral valve repairMitral regurgitationEjection fractionbusiness.industryMortality rateMitral Valve Insufficiencymedicine.diseaseTreatment OutcomeHeart failureQuality of LifeCardiologyMitral ValveCardiology and Cardiovascular MedicinebusinessJACC: Cardiovascular Imaging
researchProduct

Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: Critical review of the literature.

2018

Venous Thromboembolism (VTE) frequently complicates the course of hematologic malignancies (HM) and its incidence is similar to that observed in high-risk solid tumors. Despite that, pharmacologic prophylaxis and treatment of VTE in patients with HM is challenging, mainly because a severe thrombocytopenia frequently complicates the course of treatments or may be present since diagnosis, thus increasing the risk of bleeding. Therefore, in this setting, safe and effective methods of VTE prophylaxis and treatment have not been well defined and hematologists generally refer to guidelines produced for cancer patients that give indications on anticoagulation in patients with thrombocytopenia. In …

medicine.medical_specialtymedicine.drug_classmedicine.medical_treatmentvenous thromboembolismLow molecular weight heparinHemorrhage030204 cardiovascular system & hematologyVte prophylaxis03 medical and health sciences0302 clinical medicineAntithromboticmedicineAnimalsHumanscardiovascular diseasesIntensive care medicineChemotherapybusiness.industryIncidence (epidemiology)IncidenceCancerAnticoagulantsHematologyVenous ThromboembolismHeparin Low-Molecular-Weightmedicine.diseaseThrombocytopeniaSevere thrombocytopeniaOncology030220 oncology & carcinogenesisHematologic NeoplasmsbusinessVenous thromboembolismCritical reviews in oncology/hematology
researchProduct

Tutorial in oral antithrombotic therapy: biology and dental implications.

2013

Objectives: Recent developments of new direct oral anticoagulants that target specific clotting factors necessitate understanding of coagulation biology. The objective of this tutorial is to offer dental professionals a review of coagulation mechanisms and the pharmacodynamics of the conventional and new oral anticoagulants. Also, we summarized the dental implications of the conventional and new anticoagulants. Method: We searched Medline using search terms “antithrombotic”, “antihemostasis” or “anticoagulation” and combined them with the search results of “dental”, “oral surgery” or “periodontal”. We restricted the results to “human” and “English”. Results: The early coagulation cascade, t…

medicine.medical_specialtymedicine.drug_mechanism_of_actionFactor Xa InhibitorOral Surgical ProceduresAdministration OralOdontologíaHemorrhage030204 cardiovascular system & hematologyOral Surgical Procedures03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRisk FactorsAntithromboticmedicineHumansIntensive care medicineGeneral DentistryClotting factorbusiness.industryWarfarinReview-Article030206 dentistryPerioperative:CIENCIAS MÉDICAS [UNESCO]Ciencias de la salud3. Good healthSurgerystomatognathic diseasesOtorhinolaryngologyDirect thrombin inhibitorUNESCO::CIENCIAS MÉDICASSurgeryOral SurgerybusinessFibrinolytic agentmedicine.drugMedicina oral, patologia oral y cirugia bucal
researchProduct

Measurement of coagulation factors during rivaroxaban and apixaban treatment: Results from two crossover trials

2018

Abstract Background Prediction models for venous thromboembolism recurrence will likely be improved by adding levels of coagulation factors. Risk assessment is ideally performed during anticoagulant treatment, however, the influence of direct oral anticoagulants on coagulation factors is uncertain. Objective To assess the influence of rivaroxaban and apixaban on several coagulation factor levels. Methods In two crossover trials we assessed the influence of rivaroxaban and apixaban intake on factor (F)VIII, FXI and FXII‐activity and fibrinogen, von Willebrand factor (VWF:Ag), and d‐dimer levels. At three sessions with a washout period in between, blood was taken from 12 healthy male individu…

medicine.medical_specialtymedicine.drug_mechanism_of_actionFactor Xa Inhibitorapixabanfactor Xa inhibitors030204 cardiovascular system & hematologyTreatment resultsFibrinogenGastroenterology03 medical and health sciences0302 clinical medicineVon Willebrand factorInternal medicinecoagulantsMedicinerivaroxabanBlood coagulation testRivaroxabanbiologybusiness.industryBrief Reportblood coagulation testsrisk assessmentHematologyCoagulation030220 oncology & carcinogenesisbiology.proteinApixabanbusinessOriginal Articles: Thrombosismedicine.drug
researchProduct

Cigarette smoke-induced pulmonary endothelial dysfunction is partially suppressed by sildenafil.

2009

Abstract Cigarette smoke mediated oxidative stress and endothelial dysfunction are important processes in the pathogenesis of several lung disorders. In this study we evaluated the effect of PDE5 inhibition on pulmonary artery endothelial dysfunction induced by cigarette smoke in vitro . Human pulmonary artery endothelial cells (HPAEC) were incubated in the absence or presence of PDE5 inhibitor sildenafil (10 nM–1 μM), PKG agonist 8-Br-cGMP (1 mM), or the antioxidants dyphenyleneiodonium (DPI 1 μM) and N -acetylcysteine (NAC 1 mM) for 30 min. Then, cigarette smoke extract (CSE) was added for 24 h. CSE (2.5–10%)-induced ROS generation was suppressed by DPI, and partially reversed by sildenaf…

medicine.medical_specialtymedicine.drug_mechanism_of_actionSildenafilVasodilator AgentsPharmaceutical ScienceEnzyme-Linked Immunosorbent Assaymedicine.disease_causeNitric OxidePolymerase Chain ReactionPiperazinesSildenafil CitrateAcetylcysteinechemistry.chemical_compoundInternal medicineSmokeparasitic diseasesTobaccomedicineHumansSulfonesEndothelial dysfunctionPhosphodiesterase inhibitorLungCells CulturedDNA PrimersbiologyBase Sequencebusiness.industrymedicine.diseaseEndothelial stem cellEndocrinologychemistryEnzyme inhibitorPurinescardiovascular systembiology.proteinEndothelium VascularbusinessPhosphodiesterase 5 inhibitorOxidative stressmedicine.drugEuropean journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
researchProduct